New Board members will provide expert insight into ADME-Tox, biomarker, assay, cell and gene therapy, and immuno-oncology advances
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced the launch of its new Scientific Advisory Board (SAB) comprised of experts in ADME-Tox, drug development, cell and gene therapy, immuno-oncology, and clinical diagnostics.